Company Description
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East.
The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk.
The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012.
Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
Country | United States |
Founded | 1982 |
IPO Date | Nov 18, 1996 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 134 |
CEO | Jack Phillips |
Contact Details
Address: 3950 South Country Club Road, Suite 470 Tucson, Arizona 85714 United States | |
Phone | 520 365 3100 |
Website | acceleratediagnostics.com |
Stock Details
Ticker Symbol | AXDX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000727207 |
CUSIP Number | 00430H102 |
ISIN Number | US00430H2013 |
Employer ID | 84-1072256 |
SIC Code | 3826 |
Key Executives
Name | Position |
---|---|
Jack Phillips | Chief Executive Officer, President and Director |
David Patience | Chief Financial Officer |
Lawrence Michael Mertz | Chief Technology Officer |
Maya Gowri | Senior Vice President and Head of Operations |
John Meduri | Chief Strategy Officer |
Chris Thode | Senior Vice President of US Commercial |
Rita Boukamel | Senior Vice President and Head of EMEA |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Nov 7, 2024 | 10-Q | Quarterly Report |
Nov 7, 2024 | 8-K | Current Report |
Sep 30, 2024 | 8-K | Current Report |
Aug 26, 2024 | 8-K | Current Report |
Aug 12, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Aug 8, 2024 | 10-Q | Quarterly Report |
Aug 8, 2024 | 8-K | Current Report |
Aug 8, 2024 | 8-K | Current Report |
Jun 5, 2024 | 8-K | Current Report |